---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-019102"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2026-06-02T12:04:53+00:00"
generated_at: "2026-06-02T12:11:27.712432+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# UroGen settles patent litigation with Teva over Jelmyto; generic entry Sept 15, 2030

## Summary
- Settlement resolves patent litigation regarding Teva's generic version of Jelmyto (mitomycin) for pyelocalyceal solution.
- Teva granted non-exclusive license to sell generic Jelmyto starting September 15, 2030, if FDA approved.
- All ongoing patent litigation between the parties in U.S. District Court for Delaware will be terminated.
- Agreement is subject to review by U.S. Federal Trade Commission and U.S. Department of Justice.

## SEC filing metadata
- accession: 0001437749-26-019102
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2026-06-02T12:04:53+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774926019102/0001437749-26-019102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774926019102/urgn20260601_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-019102
- JSON: https://secwatch.observer/filing/0001437749-26-019102.json
- Plain text: https://secwatch.observer/filing/0001437749-26-019102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.